^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    INCB86550

    i
    Other names: INCB86550, INCB-86550, INCB-086550, INCB 086550, INCB086550
    Company:
    Incyte
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    6d
    To assess the safety, tolerability and pharmacokinetics of INCB86550 in healthy adult population. (ACTRN12621000103864)
    P1, N=75, Completed, Incyte Corporation | Not yet recruiting --> Completed
    Trial completion
    |
    itraconazole • INCB86550
    8ms
    Study of INCB086550 in Select Solid Tumors (clinicaltrials.gov)
    P2, N=16, Terminated, Incyte Corporation | Trial completion date: Aug 2024 --> Mar 2024 | Active, not recruiting --> Terminated; Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile.
    Trial completion date • Trial termination • Checkpoint inhibition
    |
    INCB86550
    1year
    A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=138, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    INCB86550
    over1year
    A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=138, Active, not recruiting, Incyte Corporation | Trial completion date: Sep 2023 --> Feb 2024
    Trial completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    INCB86550
    over1year
    Study of INCB086550 in Select Solid Tumors (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, Incyte Corporation | N=150 --> 16 | Trial completion date: May 2023 --> Aug 2024 | Trial primary completion date: May 2023 --> Mar 2024
    Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    INCB86550
    over1year
    A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=138, Active, not recruiting, Incyte Corporation | Trial completion date: Feb 2023 --> Sep 2023 | Trial primary completion date: Feb 2023 --> Sep 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    INCB86550
    almost3years
    A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=128, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    INCB86550
    over3years
    A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=128, Recruiting, Incyte Corporation | N=372 --> 128
    Clinical • Enrollment change
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    INCB86550
    over3years
    A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=372, Recruiting, Incyte Corporation | N=230 --> 372 | Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2022 --> Dec 2022
    Clinical • Enrollment change • Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    INCB86550
    almost4years
    A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=230, Recruiting, Incyte Corporation | N=128 --> 230 | Trial completion date: Aug 2021 --> Sep 2022 | Trial primary completion date: Jun 2021 --> Sep 2022
    Clinical • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    INCB86550